BALTIMORE, Jan. 14, 2025 /PRNewswire/ — Brown Advisory, an independent investment management and strategic advisory firm, today announced the next step in its leadership, with the creation of a Co-Chief Executive Officer structure. Effective immediately, Mike Hankin and Logie Fitzwilliams will share chief executive responsibilities. Mike Hankin has served as the sole CEO and President since the firm became private and independent in 1998. Logie Fitzwilliams started with Brown Advisory in 2003 and has most recently served as the Head of International Business and Global Head of Sales.

Together, the firm’s independent Board of Directors and Mike Hankin decided that a Co-CEO structure would be the best design to provide the leadership needed to meet the growing needs of the firm’s clients, colleagues and shareholders. As a team, Mike and Logie, who have worked closely together for the last 15 years, will deepen the firm’s partnership and collaborative culture to drive results for all stakeholders. This evolution represents the most significant change in Brown Advisory’s leadership since the firm adopted its current private, independent structure in 1998. As Co-CEOs – and Co-Presidents – both Mike and Logie will serve on, and report to, the Board that governs the firm.

Mike Hankin stated, “I could not be more excited about this natural next step in the leadership of the firm. In the building of a global investment team and business to complement what we have been cultivating in the U.S., Logie has led with the qualities that we think make him the ideal person to share responsibility for leadership of the entire firm. He understands that to be truly client first, we need to be obsessively focused on listening to our clients in the U.S. and around the world. He understands that to build successful teams, we need to also listen to our colleagues. We need to make sure that our colleagues have the resources and training necessary to live up to our clients’ expectations.”

He added, “Importantly, Logie and I share the existential commitment to Brown Advisory remaining a private and independent firm. Our ownership structure – where every single colleague owns equity in the firm alongside an important set of outside shareholders who provide critical advice and support – will remain the same; it is the structural backbone to being the client-first firm we aspire to be over generations.”

Logie Fitzwilliams noted, “It is a tremendous honor to join Mike in the leadership of Brown Advisory. Throughout my 22 years at the firm, I have been privileged to work with him closely and we have built a deep relationship that will serve as the foundation for our partnership as Co-CEOs. Most importantly, from the outset we have had a shared focus on investing for, advising and serving our clients at the highest possible level, and a common commitment to the future of Brown Advisory as a private, independent, entrepreneurial and nimble business.”

Bob Flanagan, Lead Director of the Brown Advisory Board, shared, “The process and thinking behind this decision was extensive, productive and always forward looking. We considered many options and scenarios to ensure that Brown Advisory had the best leadership in place for the present and future. Each of us believe that the firm, its clients and its colleagues will be best served with Mike and Logie acting as CEOs, together.”

Bea Hollond, Director and Chair of the firm’s International Advisory Board, added, “Being based in the U.K., I have had the direct opportunity to work with and advise Logie on the firm’s international business strategy. I have seen first-hand the incredible impact he has made for Brown Advisory and its clients. I know the Directors all share my excitement in welcoming Logie to the Board, and to seeing Mike and Logie work together as a team.”

Under Mike Hankin’s leadership, the firm has grown from overseeing client assets of $2 billion in 1998 to now almost $170 billion – representing an annualized growth rate of 17%. Today, the firm’s clients are served by nearly 1,000 colleagues located in 14 offices across the United States, a significant office in London and strategic bases in Frankfurt, Singapore and Tokyo. The firm’s clients – a collection of individuals, families, nonprofits, charities, institutions and financial intermediaries – are located in 51 countries and in every U.S. state. Brown Advisory also manages meaningful fund platforms – private funds, mutual funds and now ETFs – in the U.S., as well as platforms outside of the U.S. in Ireland, Bermuda and the Cayman Islands. Over the past ten years, the firm’s client-retention rate exceeds 98% through its commitment to deliver first-rate investment performance, thoughtful strategic advice and the highest level of service for clients.

Quintin Ings-Chambers will take over as Head of the International Business. Quintin joined Brown Advisory in 2012 as Head of the firm’s International Private Client and Charity business. He has over 25 years of investment industry experience. Prior to joining Brown Advisory, he served as an Investment Director at SG Hambros and as a Director in the private client and charity group of Baring Asset Management. Quintin will report into Logie Fitzwilliams.

About Brown Advisory 

Advertisement

Brown Advisory is an independent investment management and strategic advisory firm committed to providing its clients with a combination of investment performance, strategic advice and the highest level of service. Brown Advisory has been a private and independent firm since 1998. Today, the firm has more than 950 colleagues – each with an equity interest – serving private clients and institutions in over 50 countries from 18 offices globally and is responsible for approximately US$170 billion in assets for private and institutional clients and charities as of December 31, 2024. The firm’s colleague equity ownership, experienced investment professionals and client-first culture help to make a material difference in the lives of its clients. For more information, please visit www.brownadvisory.com.

Photo – https://mma.prnewswire.com/media/2597627/Brown_Advisory__Logie_Fitzwilliams_and_Mike_Hankin.jpg

Advertisement

View original content:https://www.prnewswire.co.uk/news-releases/brown-advisory-appoints-logie-fitzwilliams-co-ceo-to-serve-alongside-long-time-ceo-mike-hankin-302350516.html

Issued on behalf of Lithium South Development Corporation

VANCOUVER, BC, Jan. 14, 2025 /PRNewswire/ — USA News Group – After a challenging two years of decline, industry analysts are forecasting 2025 to be a potential turning point for the global lithium market. Shifting supply dynamics are expected to reduce the current oversupply significantly, with projections suggesting a surplus of roughly 80,000 tonnes of lithium carbonate equivalent (LCE) in 2025, down from nearly 150,000 tonnes in 2024. Experts warn that a supply shortage may emerge in the near future, with Benchmark analysts highlighting the need for $116 billion in investments by 2030 to meet anticipated electric vehicle (EV) production targets. As demand for EVs and energy storage solutions gains momentum in 2025, attention is refocusing on key players in the lithium sector, including Lithium South Development Corporation (TSXV:LIS) (OTC:LISMF), Arcadium Lithium plc (NYSE: ALTM), Sigma Lithium Corporation (NASDAQ: SGML), Lithium Americas Corp. (NYSE: LAC) (TSX: LAC), and Atlas Lithium Corporation (NASDAQ: ATLX).

The article continued: According to Precedence Research, the global lithium market is projected to reach approximately $28.45 billion by 2033, driven by a robust compound annual growth rate (CAGR) of 12.50%. Bank of America has also forecasted a shift toward a lithium supply deficit by 2027, noting that 2025 may mark the peak of the current oversupply.

Lithium South Development Corporation (TSXV:LIS) (OTC:LISMF) recently announced the signing of a Letter of Intent (LOI) with a private European corporation with strong financing abilities for the cooperative development of its flagship Hombre Muerto North Lithium Project (HMN Li Project), located in Salta Province, Argentina.

As per the deal, on a best-efforts basis Lithium South’s partner in this LOI will procure a capital loan for up to US$10 million for the completion of a Definitive Feasibility Study (DFS) on the HMN Li Project, and then also will procure project funding for 80% of the CAPEX as defined in the DFS after it’s published.

Back in November, Lithium South provided an update on the HMN Li, through a bulk sample taken from 10 pilot evaporation ponds that have been concentrating since December 2022. Their technical team began harvesting the concentrated brine for removal to Salta, where the process will involve the use of Geotanks for each sample of interest, with approximately 19 cubic metres of brine per Geotank.

It was during this same corporate update that Lithium South mentioned it was in continuing discussions with interested parties, which likely led to the announced LOI. These discussions also involved a planned December site visit with one of the interested parties.

“With a solid lithium resource and industry leading brine chemistry, recent M and A activity within the lithium industry underscores the value proposition of the HMN Li Project,” said Adrian F. C. Hobkirk, President and CEO of Lithium South. “With the recent completion of a Phase One Environmental Baseline Study, the Company is hoping to advance the project to a Definitive Feasibility Study. Lithium South is funded well into 2025.”

CONTINUED… Read this and more news for Lithium South. at: 
https://equity-insider.com/2023/10/17/unlock-2024s-hot-lithium-project-li-resource-expanded-by-175/ 

Arcadium Lithium plc (NYSE: ALTM), recently moved closer to being acquired by Rio Tinto after it received clearance from the Committee on Foreign Investment in the United States (CFIUS) determining that there are no unresolved national security concerns with the proposed acquisition. The clearance came less than a month after Arcadium’s shareholders approved the acquisiton.

Advertisement

“Today’s vote of support by our shareholders confirms our shared belief that with Rio Tinto, we will be a stronger global leader in lithium chemicals production,” said Paul Graves, President and CEO of Arcadium Lithium. “Together, we enhance our capabilities to successfully develop and operate our assets while supporting the clean energy transition. We are confident that this transaction will provide future benefit to our customers, employees and the communities in which we operate, and I am excited by the path ahead.”

Sigma Lithium Corporation (NASDAQ: SGML), a leading global lithium producer, ended 2024 by announcing it had exceeded its Q4 2024 targets with 75,000 tonnes of quintuple zero green lithium produced, and being positioned to surpass 270,000 tonnes in 2025. With its strong operational performance and commitment to sustainable growth, Sigma Lithium is well-positioned to exceed its 2025 production target of 270,000 tonnes.

“With the successful completion of the fourth quarter, we are demonstrating mastery of our innovative green industrialization technologies for lithium processing and dense media separation,” said Ana Cabral, CEO and Co-Chairman of Sigma Lithium. “Our Greentech Industrial Plant is delivering lithium materials that are aligned with the ethos of the consumers of the electric vehicles, and this gives our team a tremendous sense of purpose and accomplishment. Exceeding production and commercial targets in the fourth quarter has reinforced our confidence in our ability to surpass our 2025 production targets. This remarkable year is a testament to the relentless pursuit of excellence by a highly dedicated team, showing that innovation thrives in diverse work environments.”

Lithium Americas Corp. (NYSE: LAC) (TSX: LAC), recently increased its Mineral Resource and Reserve for its Thacker Pass project in Nevada, through the release of a new NI 43-1010 Technical Report on the Nevada asset, which the company shares ownership (62%) with General Motors holding 38%. As per the new report, Thacker Pass has a Proven and Probable mineral reserve estimate of 14.3 million tonnes lithium carbonate equivalent (LCE) for an increase of 286% from the 2022 Feasability Study, and a Measured and Indicated mineral resource estimate of 44.5 million tonnes LCE, for an increase of 177%.

“We are excited to release the results of our Thacker Pass Technical Report that demonstrates the multigenerational opportunity for transformational growth the Project creates,” said Jonathan Evans, President and CEO of Lithium Americas. “Thacker Pass is now the largest measured lithium reserve and resource in the world and has the potential to become an unmatched district, generating American jobs and helping the U.S. regain independence of its energy supply. We are committed to safely and sustainably developing Thacker Pass while engaging with our stakeholders to increase domestic production of critical minerals.”

Atlas Lithium Corporation (NASDAQ: ATLX) continues to make strides forward in its journey to become a leading lithium producer at its Neves Project in Brazil’s Lithium Valley, recently adding Eduardo Queiroz as Project Management Officer and Vice President of Engineering, and expanding its Asian Market presence by adding Beijing-based Lili Wu as Head of Business Development for Asia.

Prior to these additions, Atlas Lithium outlined its medium to long-term regional growth strategy for Neves. Over the last several years, Atlas Lithium has assembled Brazil’s largest portfolio of lithium mineral rights among publicly listed companies. Now Neves has been permitted and is advancing towards production, while its Salinas Project and Clear Project both have potential for spodumene deposits.

“Our deposits at the Neves Project are distinguished by large spodumene crystals, which should enable a streamlined production process and deliver lithium concentrate with minimal impurities,” said Raimundo Almeida, Vice President of Lithium Processing at Atlas Lithium. “This attribute makes our future product particularly attractive to lithium refiners. The latest discoveries across our Lithium Valley project portfolio, especially the high-grade results from initial exploration at the Salinas Project, further demonstrate the effectiveness of our methodical approach in identifying high-potential spodumene deposits.”

Source: https://equity-insider.com/2023/10/17/unlock-2024s-hot-lithium-project-li-resource-expanded-by-175/ 

CONTACT:
USA NEWS GROUP
[email protected]
(604) 265-2873

Advertisement

DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. Equity Insider is a wholly-owned subsidiary of Market IQ Media Group, Inc. (“MIQ”). MIQ has been paid a fee for Lithium South Development Corporation advertising and digital media from the company directly. There may be 3rd parties who may have shares of Lithium South Development Corporation, and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ own shares of Lithium South Development Corporation which were purchased as a part of a private placement and in the open market. MIQ reserves the right to buy and sell, and will buy and sell shares of Lithium South Development Corporation at any time thereafter without any further notice. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material disseminated by MIQ has been approved by the above mentioned company; this is a paid advertisement, and we own shares of the mentioned company that we will sell, and we also reserve the right to buy shares of the company in the open market, or through further private placements and/or investment vehicles. The contents of this advertisement were reviewed by Mr. William Feyerabend, a Consulting Geologist and Qualified Person as defined under National Instrument 43-101. Mr. Feyerabend approves of the scientific and technical disclosure pertaining to Lithium South contained within this advertisement. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.

View original content:https://www.prnewswire.co.uk/news-releases/lithiums-role-in-the-energy-revolution-to-regain-momentum-in-2025-302350482.html

LONDON, Jan. 14, 2025 /PRNewswire/ — Montagu announced today its intention to create a world-leading medical devices supplier by supporting the merger of Tyber Medical, Intech and Resolve Surgical Technologies (“Resolve”).

As part of the transaction, Montagu entered into a definitive agreement to acquire Tyber Medical, an innovative medical device company providing private label development and manufacturing services to med-tech Original Equipment Manufacturers (OEMs). Subject to customary regulatory approvals and closing conditions, Tyber Medical will be combined with Montagu’s existing investments in Resolve, a leading provider of contract device design, manufacturing, and lifecycle management services, as well as in Intech, a leader in the co-development and manufacturing of complex orthopaedic surgical devices.

The combined entity will offer a unique mix of proprietary market-cleared technologies, and development and manufacturing scale, that will enable its OEM customers to achieve unmatched speed to market and improve the resiliency and effectiveness of their supply chain. At the time of the merger, the platform will be a leading contract supplier of systems for Spine, Trauma, Extremities, Sports Medicine and Enabling Technologies, with plans to expand its pioneering innovation-led model into additional markets. The planned merger will support accelerated innovation and help improve standards of care for patients globally.

Jeff Tyber, Founder and CEO at Tyber Medical said: “Tyber Medical’s proven track record of successful global launches, averaging 12 months from signing to launch, has revolutionized how our partners expand their portfolios and adapt to the evolving market dynamics. This strategic combination brings together the size, scale, and expertise of Intech, along with Resolve’s deep knowledge in the Spine and Cardiothoracic fields. We are delighted to be partnering with Montagu, a leading investment firm in the private label OEM sector, and we share their vision of creating an industry champion.”

“This unique combination represents a significant milestone, enhancing our ability to serve medical technology companies worldwide,” said Laurent Pruvost, President and CEO of Intech. “By combining Intech’s global manufacturing footprint and know-how with Resolve and Tyber’s tailored solutions, we will establish ourselves as the undisputed partner of choice in the industry.”

Megan Osorio, President and CEO of Resolve said: “Bringing innovation to market with speed and quality is of the utmost importance to our OEM customers. Joining forces will increase our ability to support their growth across the full range of orthopaedic implants & instruments by bringing the deep experience of our respective teams and scale of our manufacturing footprint together.”

Adrien Sassi, Partner at Montagu said: “Montagu is proud to support the creation of this world-class medical device platform. The three organisations share similar passion and focus on delivering innovative, high-quality, reliable solutions to OEM customers, surgeons, and patients. We look forward to partnering with Jeff Tyber and his talented team, as well as extending our successful collaboration with Intech and Resolve.”

Houlihan Lokey and Dechert LLP, respectively, acted as exclusive financial advisor and legal advisor to Tyber Medical. Weil Gotshal & Manges acted as legal advisor to Montagu, Intech and Resolve.

Media enquiries

Greenbrook: James Madsen and Cecilie Oerting
+44 20 7952 2000 | [email protected]

Advertisement

About Intech

Intech is a global leader in the manufacturing of orthopaedic devices and mission-critical components. With facilities in the USA, Europe, and Asia-Pacific, the group excels in producing surgical implants, instruments, cutting tools, handles, and sterilization containers. With innovation at heart, Intech is at the forefront of contract-design and contract-manufacturing in the field of Orthopaedics and Healthcare. Intech is also home to SMADE, its IoMT division that offers smart tracking of geolocation, sterilisation cycles, and usage of surgical containers on the field. For more information, visit https://intech-medical.com/.

About Resolve Surgical Technologies

Resolve Surgical Technologies is an industry-leading private label OEM that designs, develops and manufactures metal and polymer implants and instruments serving the orthopaedics, spine and cardiothoracic markets. Originally founded in 1992 as Pioneer Surgical Technology, Inc. and later known as the Metals division of RTI Surgical, Resolve became known for their innovative designs and engineering expertise. Today, Resolve Surgical focuses on creating value as an extension of our OEM partners’ teams to deliver innovation, accelerate speed to revenue and drive lifecycle management with robust quality and regulatory support. For more information, visit www.resolvesurg.com.

About Tyber Medical LLC

Tyber Medical LLC is a leading orthopaedic device manufacturer providing rapid access to FDA-cleared and CE-marked, private label, portfolio-enhancing regulatory-approved orthopaedic implants for the spinal, extremity, and trauma markets. Since its founding in 2012, the company has released more than 50 spine, extremity, and trauma systems. Tyber Medical aims to develop and utilize differentiated bioengineered technologies, including surface treatments and coatings, to advance orthopaedic science. For more information, visit https://tybermedical.com/.

About Montagu

Montagu is a leading mid-market private equity firm, committed to finding and growing businesses that make the world work. Focussing on businesses with a must-have product or service in a structurally growing marketplace, Montagu brings proven growth capabilities to help companies achieve their ambitions and unlock their full potential. Montagu specialises in carve-out and other first time buyout investments and has deep expertise in five priority sectors: Healthcare, Financial Sector Services, Critical Data, Digital Infrastructure and Education. ESG forms an integral part of its strategy, and its commitment to responsible investment is fully integrated into its investment and value-creation process. Montagu partners with companies with enterprise values between €200 million and €1 billion and has €12bn assets under management. For additional information on Montagu, visit www.montagu.com

Advertisement

View original content:https://www.prnewswire.co.uk/news-releases/tyber-medical-intech-and-resolve-surgical-technologies-combine-to-form-a-next-generation-solutions-provider-to-the-medical-device-industry-302350537.html